305 related articles for article (PubMed ID: 24796150)
21. Practical Use of Pharmacotherapy for Obesity.
Igel LI; Kumar RB; Saunders KH; Aronne LJ
Gastroenterology; 2017 May; 152(7):1765-1779. PubMed ID: 28192104
[TBL] [Abstract][Full Text] [Related]
22. Orlistat for obesity.
Med Lett Drugs Ther; 1999 Jun; 41(1055):55-6. PubMed ID: 10436767
[No Abstract] [Full Text] [Related]
23. New and emerging drug molecules against obesity.
George M; Rajaram M; Shanmugam E
J Cardiovasc Pharmacol Ther; 2014 Jan; 19(1):65-76. PubMed ID: 24064009
[TBL] [Abstract][Full Text] [Related]
24. Nonincretin drugs in later-stage development.
Zimmerman MP; Mehr SR
Am J Manag Care; 2014 Jan; 20(1 Spec No.):E2. PubMed ID: 25618226
[No Abstract] [Full Text] [Related]
25. Drug treatment of obesity.
Bray GA
Baillieres Best Pract Res Clin Endocrinol Metab; 1999 Apr; 13(1):131-48. PubMed ID: 10932681
[TBL] [Abstract][Full Text] [Related]
26. ACS chemical neuroscience molecule spotlight on Qnexa.
Mercer SL
ACS Chem Neurosci; 2011 Apr; 2(4):183-4. PubMed ID: 22778866
[TBL] [Abstract][Full Text] [Related]
27. A Comparison of New Pharmacological Agents for the Treatment of Obesity.
Nuffer W; Trujillo JM; Megyeri J
Ann Pharmacother; 2016 May; 50(5):376-88. PubMed ID: 26887340
[TBL] [Abstract][Full Text] [Related]
28. Lorcaserin, phentermine topiramate combination, and naltrexone bupropion combination for weight loss: the 15-min challenge to sort these agents out.
Citrome L
Int J Clin Pract; 2014 Dec; 68(12):1401-5. PubMed ID: 25418525
[No Abstract] [Full Text] [Related]
29. Topiramate and phentermine: a long story...
Prescrire Int; 2013 Mar; 22(136):62. PubMed ID: 23593687
[No Abstract] [Full Text] [Related]
30. Safety and tolerability of medications approved for chronic weight management.
Fujioka K
Obesity (Silver Spring); 2015 Apr; 23 Suppl 1():S7-11. PubMed ID: 25900872
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the Efficacy of Anti-Obesity Medications in Real-World Practice.
Song JE; Ko HJ; Kim AS
Drug Des Devel Ther; 2024; 18():845-858. PubMed ID: 38524878
[TBL] [Abstract][Full Text] [Related]
32. Pharmacotherapy of obesity: Available medications and drugs under investigation.
Pilitsi E; Farr OM; Polyzos SA; Perakakis N; Nolen-Doerr E; Papathanasiou AE; Mantzoros CS
Metabolism; 2019 Mar; 92():170-192. PubMed ID: 30391259
[TBL] [Abstract][Full Text] [Related]
33. Pharmacotherapy for obesity in individuals with type 2 diabetes.
Chukir T; Shukla AP; Saunders KH; Aronne LJ
Expert Opin Pharmacother; 2018 Feb; 19(3):223-231. PubMed ID: 29376439
[TBL] [Abstract][Full Text] [Related]
34. Obesity Epidemic: Pharmaceutical Weight Loss.
Curry SA
R I Med J (2013); 2017 Mar; 100(2):18-20. PubMed ID: 28246654
[TBL] [Abstract][Full Text] [Related]
35. Regulation of food intake and the development of anti-obesity drugs.
Chen Y
Drug Discov Ther; 2016; 10(2):62-73. PubMed ID: 27063550
[TBL] [Abstract][Full Text] [Related]
36. New obesity agents: lorcaserin and phentermine/topiramate.
Fleming JW; McClendon KS; Riche DM
Ann Pharmacother; 2013; 47(7-8):1007-16. PubMed ID: 23800750
[TBL] [Abstract][Full Text] [Related]
37. Comparison table: some FDA-approved drugs for weight management.
Med Lett Drugs Ther; 2018 Jun; 60(1548):e98-e100. PubMed ID: 29913464
[No Abstract] [Full Text] [Related]
38. Horizons in the Pharmacotherapy of Obesity.
Arch JR
Curr Obes Rep; 2015 Dec; 4(4):451-9. PubMed ID: 26346394
[TBL] [Abstract][Full Text] [Related]
39. Efficacy comparison of medications approved for chronic weight management.
Kumar RB; Aronne LJ
Obesity (Silver Spring); 2015 Apr; 23 Suppl 1():S4-7. PubMed ID: 25900871
[TBL] [Abstract][Full Text] [Related]
40. Obesity: The New Global Epidemic Pharmacological Treatment, Opportunities and Limits for Personalized Therapy.
Milano W; De Biasio V; Di Munzio W; Foggia G; Capasso A
Endocr Metab Immune Disord Drug Targets; 2020; 20(8):1232-1243. PubMed ID: 32410565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
